VENOUS THROMBOEMBOLISM IN WOMEN USING HORMONAL CONTRACEPTION. FINDINGS FROM A SINGLE CENTER
(Abstract release date: 05/19/16)
EHA Library. A. 06/09/16; 135112; PB2212
Ms. Alba Sara
Contributions
Contributions
Abstract
Abstract: PB2212
Type: Publication Only
Background
Venous thrombosis including deep-vein thrombosis (DVT) and pulmonary embolism (PE) is considered a multifactorial disease associated with genetic and acquired risk factors. In women of reproductive age, the main cause of venous thromboembolic disease (VTD) is the hormonal contraception. However, other risk factors interact to produce VTD.
Aims
Identifying the risk factors for DVT and PE, may intervene in risk situations and limit the occurrence of VTD with its potential morbidity and mortality.
Methods
We reviewed the characteristics of our series of 103 women with objectively confirmed VTD associated with hormonal contraception. We analyzed its clinical data and thrombophilia studies which were performed in more than 80% of them and included anticoagulant proteins, genetic tests, antiphospholipid antibodies and factor VIII level. Statistical analysis was performed with SPSS 18.0 software. bidi-font-size:12.0pt;font-family:Calibri;mso-ansi-language:EN'>
Results
The mean age of our patients was 29 ± 7.4 years old. A high percent of them (46%) had a body mass index > 25 Kg/ m². The most important clinical risk factors for venous thromboembolism were inmmobility (31%), family history (27%) and polycystic syndrome (9.8%). The combined oral contraceptive including antiandrogen and third generation progestogen were the most frecuently used for our patients. Thromobophilia test revealed factor V Leiden in 13%, prothrombin mutation in 20%, antiphospholipid syndrome in 3%, protein C deficiency in 0%, protein S deficiency in 2.4%, antithrombin deficiency in 0% and increased factor VIII (>195%) in 18.7%.
Conclusion
Contraceptive use remains the most important risk factor for VTD in women of reproductive age. We observe additional risk factors such as obesity, immobilization, polycystic ovary syndrome or family history of VTD and certain thrombophilic defects. G20210A prothrombin and G1691A factor V Leiden mutations as well as elevated factor VIII (which has been associated to blood group non O) are frequent in women at a fertile age and should be part of thrombophilia study. Defining high risk patients may improve interventions in risk situations (e.g. administering antithrombotic prophylaxis or discontinuing contraceptive use after lower limb trauma) in order to prevent VTD. Finally, the increased thrombotic risk of antiandrogen and third generation contraceptives should be also taken into account.
Session topic: E-poster
Keyword(s): Hormone therapy, Risk factor, Thrombophilia, Venous thromboembolism
Type: Publication Only
Background
Venous thrombosis including deep-vein thrombosis (DVT) and pulmonary embolism (PE) is considered a multifactorial disease associated with genetic and acquired risk factors. In women of reproductive age, the main cause of venous thromboembolic disease (VTD) is the hormonal contraception. However, other risk factors interact to produce VTD.
Aims
Identifying the risk factors for DVT and PE, may intervene in risk situations and limit the occurrence of VTD with its potential morbidity and mortality.
Methods
We reviewed the characteristics of our series of 103 women with objectively confirmed VTD associated with hormonal contraception. We analyzed its clinical data and thrombophilia studies which were performed in more than 80% of them and included anticoagulant proteins, genetic tests, antiphospholipid antibodies and factor VIII level. Statistical analysis was performed with SPSS 18.0 software. bidi-font-size:12.0pt;font-family:Calibri;mso-ansi-language:EN'>
Results
The mean age of our patients was 29 ± 7.4 years old. A high percent of them (46%) had a body mass index > 25 Kg/ m². The most important clinical risk factors for venous thromboembolism were inmmobility (31%), family history (27%) and polycystic syndrome (9.8%). The combined oral contraceptive including antiandrogen and third generation progestogen were the most frecuently used for our patients. Thromobophilia test revealed factor V Leiden in 13%, prothrombin mutation in 20%, antiphospholipid syndrome in 3%, protein C deficiency in 0%, protein S deficiency in 2.4%, antithrombin deficiency in 0% and increased factor VIII (>195%) in 18.7%.
Conclusion
Contraceptive use remains the most important risk factor for VTD in women of reproductive age. We observe additional risk factors such as obesity, immobilization, polycystic ovary syndrome or family history of VTD and certain thrombophilic defects. G20210A prothrombin and G1691A factor V Leiden mutations as well as elevated factor VIII (which has been associated to blood group non O) are frequent in women at a fertile age and should be part of thrombophilia study. Defining high risk patients may improve interventions in risk situations (e.g. administering antithrombotic prophylaxis or discontinuing contraceptive use after lower limb trauma) in order to prevent VTD. Finally, the increased thrombotic risk of antiandrogen and third generation contraceptives should be also taken into account.
Session topic: E-poster
Keyword(s): Hormone therapy, Risk factor, Thrombophilia, Venous thromboembolism
Abstract: PB2212
Type: Publication Only
Background
Venous thrombosis including deep-vein thrombosis (DVT) and pulmonary embolism (PE) is considered a multifactorial disease associated with genetic and acquired risk factors. In women of reproductive age, the main cause of venous thromboembolic disease (VTD) is the hormonal contraception. However, other risk factors interact to produce VTD.
Aims
Identifying the risk factors for DVT and PE, may intervene in risk situations and limit the occurrence of VTD with its potential morbidity and mortality.
Methods
We reviewed the characteristics of our series of 103 women with objectively confirmed VTD associated with hormonal contraception. We analyzed its clinical data and thrombophilia studies which were performed in more than 80% of them and included anticoagulant proteins, genetic tests, antiphospholipid antibodies and factor VIII level. Statistical analysis was performed with SPSS 18.0 software. bidi-font-size:12.0pt;font-family:Calibri;mso-ansi-language:EN'>
Results
The mean age of our patients was 29 ± 7.4 years old. A high percent of them (46%) had a body mass index > 25 Kg/ m². The most important clinical risk factors for venous thromboembolism were inmmobility (31%), family history (27%) and polycystic syndrome (9.8%). The combined oral contraceptive including antiandrogen and third generation progestogen were the most frecuently used for our patients. Thromobophilia test revealed factor V Leiden in 13%, prothrombin mutation in 20%, antiphospholipid syndrome in 3%, protein C deficiency in 0%, protein S deficiency in 2.4%, antithrombin deficiency in 0% and increased factor VIII (>195%) in 18.7%.
Conclusion
Contraceptive use remains the most important risk factor for VTD in women of reproductive age. We observe additional risk factors such as obesity, immobilization, polycystic ovary syndrome or family history of VTD and certain thrombophilic defects. G20210A prothrombin and G1691A factor V Leiden mutations as well as elevated factor VIII (which has been associated to blood group non O) are frequent in women at a fertile age and should be part of thrombophilia study. Defining high risk patients may improve interventions in risk situations (e.g. administering antithrombotic prophylaxis or discontinuing contraceptive use after lower limb trauma) in order to prevent VTD. Finally, the increased thrombotic risk of antiandrogen and third generation contraceptives should be also taken into account.
Session topic: E-poster
Keyword(s): Hormone therapy, Risk factor, Thrombophilia, Venous thromboembolism
Type: Publication Only
Background
Venous thrombosis including deep-vein thrombosis (DVT) and pulmonary embolism (PE) is considered a multifactorial disease associated with genetic and acquired risk factors. In women of reproductive age, the main cause of venous thromboembolic disease (VTD) is the hormonal contraception. However, other risk factors interact to produce VTD.
Aims
Identifying the risk factors for DVT and PE, may intervene in risk situations and limit the occurrence of VTD with its potential morbidity and mortality.
Methods
We reviewed the characteristics of our series of 103 women with objectively confirmed VTD associated with hormonal contraception. We analyzed its clinical data and thrombophilia studies which were performed in more than 80% of them and included anticoagulant proteins, genetic tests, antiphospholipid antibodies and factor VIII level. Statistical analysis was performed with SPSS 18.0 software. bidi-font-size:12.0pt;font-family:Calibri;mso-ansi-language:EN'>
Results
The mean age of our patients was 29 ± 7.4 years old. A high percent of them (46%) had a body mass index > 25 Kg/ m². The most important clinical risk factors for venous thromboembolism were inmmobility (31%), family history (27%) and polycystic syndrome (9.8%). The combined oral contraceptive including antiandrogen and third generation progestogen were the most frecuently used for our patients. Thromobophilia test revealed factor V Leiden in 13%, prothrombin mutation in 20%, antiphospholipid syndrome in 3%, protein C deficiency in 0%, protein S deficiency in 2.4%, antithrombin deficiency in 0% and increased factor VIII (>195%) in 18.7%.
Conclusion
Contraceptive use remains the most important risk factor for VTD in women of reproductive age. We observe additional risk factors such as obesity, immobilization, polycystic ovary syndrome or family history of VTD and certain thrombophilic defects. G20210A prothrombin and G1691A factor V Leiden mutations as well as elevated factor VIII (which has been associated to blood group non O) are frequent in women at a fertile age and should be part of thrombophilia study. Defining high risk patients may improve interventions in risk situations (e.g. administering antithrombotic prophylaxis or discontinuing contraceptive use after lower limb trauma) in order to prevent VTD. Finally, the increased thrombotic risk of antiandrogen and third generation contraceptives should be also taken into account.
Session topic: E-poster
Keyword(s): Hormone therapy, Risk factor, Thrombophilia, Venous thromboembolism
{{ help_message }}
{{filter}}